White paper

25 October 2022, Munich - With inflation all over the news, it is only natural that most companies expect their input prices to increase. An article published by The Economist a few months ago shows that this will likely be an enduring phenomenon. In our last article published on September 8th, we hinted that a more optimistic outlook may be merited for the API market...Ever since, we’ve updated the index on a monthly basis using the latest market prices from the QYOBO platform. Based on July data, the index showed a slight relaxation down to 5.1% (vs. the previously recorded 5.2% in April). August data – indicating another slight decrease to 5.0% – further supports this trend...

8 September 2022, Munich - Hence it does not come as a surprise that the most common question we’ve received from our clients over the course of this year was: “How is inflation affecting API prices, are you seeing similar price increases compared to overall inflation?” To answer this question QYOBO created the “QYOBO 300 index” tracking the prices of the 300 APIs most commonly analyzed by our users on the QYOBO platform...

31 March 2022, Munich - Hence one may assume that the additional demand resulting from UDCA treatment during the corona pandemic would drive prices upwards. However, a brief market price analysis in the QYOBO platform shows an opposite picture...

14 March 2022, Munich - Since Putin’s war of aggression against Ukraine started about two weeks ago, several of our partners asked if we can help them assess the risk of supply chain disruptions....

15 December 2021, Munich - 2060 - By this time, China plans to be climate neutral.1 One step towards this goal is the dual control of energy consumption policy, that’s been renewed by the National Development and Reform Commission (NDRC) in 2021. The Chinese government ordered the suspension of production and limited electricity by high-energy consuming industries, which led to shutdowns and power cuts in several Chinese provinces...

20 October 2021, Munich - Whether it’s fever, pain or inflammation - For all these complaints ibuprofen is a first choice medication. Therefore it’s no surprise that the nonsteroidal anti-inflammatory drug (NSAID) has been on the World Health Organization’s (WHO) list of essential medicines since 1977 and is a commonly used drug within the population.

17 August 2021, Munich - In 2018, there was a shortage of life-saving blood pressure drugs for several months following a voluntary recall announcement by the FDA for medical products containing valsartan. The Active Pharmaceutical Ingredient (API) was contaminated with N-nitrosodimethylamine (NDMA), which could cause cancer...

28 July 2021, Munich - When Dr. Baruch Bloomberg discovered the hepatitis B virus in 1965, he might not have assumed how many lives he would save in the future by developing a diagnostic test and vaccine against the virus...

04 May 2021, Munich - In 2020, prices for paracetamol increased for two main reasons - trade restrictions such as factory shutdowns and export restrictions and a spike in demand as the drug was considered the most effective analgesics treatment for CoViD-19 infections. Towards the end of 2020, an incident at one of the few remaining manufacturing sites of 4-aminophenol, a paracetamol intermediate occurred...

14 April 2021, Munich - Epilepsy is one of the most common serious neurological disorders with around 50 million people living with this diagnosis. One key medication to treat epilepsy is levetiracetam...

02 February 2021, Munich - In spring 2020, when the corona pandemic started spreading around the globe, many efforts were made to treat infected patients with existing drugs. Especially paracetamol made headlines due to recommendations by several governments and the World Health Organization.

04 November 2020, Munich - Macrolides and cephalosporins are some of the most commonly used antibiotics. During the CoViD‐19 crisis, several of these APIs like azithromycin and cefuroxime turned out to be effective in the treatment of patients infected with CoViD‐19...

22 September 2020, Munich - Losartan API prices tripled in a very short period while it was considered as a potential CoViD-19 remedy earlier this year. Other related substances have fared rather stable throughout the crisis, and one well-known “sartan” never recovered from its NDMA scandal in 2018...

20 August 2020, Munich - Prices for penicillins increased by 14-20 % during the first half of 2020 with prices for some penicillin APIs “shooting up” more than 40 %. Governments worldwide have undertaken efforts to decrease reliance on API imports from Asia...

18 June 2020, Munich - British scientists from Oxford University published a study about Dexamethasone demonstrating positive effects on patients requiring ventilation due to a corona infection...

14 May 2020, Munich - Primarily driven by lower prices for APIs manufacturing has mainly moved to India and China. The corona crisis could become a turning point for the pharmaceutical industry...

29 April 2020, Munich - Shortly after the outbreak of the corona crisis, scientists started to test existing drugs as potential remedies. Two malaria drugs received particular attention and widespread media coverage...

22 March 2020, Munich - Remedies against HIV, Malaria or high blood pressure are under evaluation in the fight of COVID-19. If proven effective...